NanoViricides Inc. (NNVC)

[KMBJN]

Nice to see the PR today testing against SARS2 (pseudovirions) that was lacking before. As always, there are questions about the PR and studies, like:

where was the work done / who did it?

will they publish all this preclinical work?

how exactly does the "study demonstrate[s] that NV-CoV-2 attacks the SARS-CoV-2 pseudovirion particles and renders them incapable of binding to the ACE2 positive cells?"

how can they tell the drug doesn't inhibit activity inside the cell or work in some other way than disruption of viral binding via ACE2?

does NV-CoV-2 go into the cell?

how can NV-CoV-2 work against different types of CoV that use different receptors to enter the cell (ACE2 and APN=CD13)?

will they be pursuing as first IND NV-CoV-2 or NV-CoV-2-R?

do they have rights to use/deliver remdesivir without a license from GILD?

will they be pursuing a pill form or IV form for IND?

what are the details of the oral form animal model studies briefly mentioned last week?

how do the pharmacokinetics differ between oral and IV administration?

can they reliably make the drug at a reasonable profit margin (see molnupiravir oral at $700/course or IV-neutralizing antibodies at around $1-3K/dose)?

what stage of Covid will they be going after? outpatient/asymptomatic/mild/high-risk, hospitalized mild/moderate, or hospitalized more severe?

what other work remains before IND submission?

and most important of all, Will they REALLY get their first IND this time? or will the pandemic be over by the time they get around to doing that?